Stockscreener 앱 받기
108.22
10.19%
-12.51
전일 마감가:
$120.73
열려 있는:
$107.53
하루 거래량:
30.00M
Relative Volume:
4.56
시가총액:
$188.13B
수익:
$43.84B
순이익/손실:
$13.90B
주가수익비율:
13.57
EPS:
7.9725
순현금흐름:
$6.92B
1주 성능:
-12.23%
1개월 성능:
-13.40%
6개월 성능:
-13.76%
1년 성능:
-7.94%
1일 변동 폭
$105.78
$114.00
1주일 범위
$105.78
$123.49
52주 변동 폭
$105.78
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.19 | 209.93B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
359.58 | 138.80B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
91.61 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
101.05 | 128.57B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.75 | 49.41B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Forecasts Lower Q1 Profit as Nutrition Discounts Hit Resu - GuruFocus
Abbott Laboratories (ABT) Eyes Growth with Strategic Moves and P - GuruFocus
Abbott Labs dips 9% as Q4 revenue misses forecasts - breakingthenews.net
Abbott Broadens Cardiology And Oncology Reach As Valuation Questions Persist - simplywall.st
Abbott’s stock falls by nearly 11% following Q4 sales miss - Yahoo Finance
Intel, GE Aerospace, Moderna, Abbott, Arista, Mobileye, McCormick, and More Movers - Barron's
Why Abbott Laboratories (ABT) Shares Are Sliding Today - The Chronicle-Journal
Abbott (ABT) Shares Decline Amid Market Activity - GuruFocus
Abbott posts Q4 sales below expectations - MedTech Dive
Abbott Laboratories Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Abbott slumps over 8% after missing Q4 revenue targets, lower Q1 forecast - Mint
Abbott Laboratories Q4 Earnings Call Highlights - Yahoo Finance
Abbott misses fourth quarter expectations amid slump in nutrition segment - chicagobusiness.com
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results - Benzinga
Abbott (ABT) Stock Declines Over 7% to $111.73 - GuruFocus
Abbott Labs Faces Setback with Q4 Revenue Miss and Cautious Guid - GuruFocus
Abbott Q4 2025 presentation slides: Revenue miss overshadows EPS growth - Investing.com
Abbott Stock Slides 7% After Q4 Results And 2026 Outlook Disappoint Investors - Nasdaq
Abbott Laboratories (ABT) Stock: Q4 Revenue Hits $11.46B but Shares Drop 7.35% - CoinCentral
Abbott (ABT) Q4 2025 Earnings Call Transcript - AOL.com
Abbott Stock Slid As 2025 Outlook Fell Short - Finimize
Stock Movers: Corcept Therapeutic, Abbott Labs, Arista Networks - Bloomberg.com
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat - FinancialContent
ABT Plans New Product Launches Amid Forecasted Nutrition Sales C - GuruFocus
Earnings call transcript: Abbott Labs Q4 2025 results miss revenue forecast - Investing.com
AI for investors - MLQ.ai
Abbott Stock Drops on Slumping Sales of Baby Formula and Nutrition Shakes - The Wall Street Journal
Abbott Dives 7% On Quarterly Upset As Exact Close Looms - Investor's Business Daily
Abbott shares slide after Q4 revenue comes in short, outlook disappoints - MSN
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls - Yahoo Finance
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints - Benzinga
Abbott Laboratories stock hits 52-week low at $107.27 By Investing.com - Investing.com India
ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth - TipRanks
Abbott (ABT) Stock Falls Following Lower-than-Expected Q1 EPS Gu - GuruFocus
Abbott Laboratories (ABT) Falls on Q4 Revenue Miss Despite Earni - GuruFocus
Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Abbott (ABT) Stock Sinks Despite EPS Match as Revenue Miss Sparks Selloff - Tokenist
Abbott Laboratories (ABT) Secures FDA Approval for Volt Device - GuruFocus
Abbott Laboratories (NYSE:ABT) Issues Quarterly Earnings Results - MarketBeat
Abbott Sales Miss Estimates on Nutrition Unit Struggles - Bloomberg
Abbott (ABT) Matches Q4 Earnings Estimates - Yahoo Finance
Abbott: Q4 Earnings Snapshot - kare11.com
Abbott Laboratories (ABT) Q4 Earnings: EPS Beats, Revenue Misses - GuruFocus
These Stocks Are Today’s Movers: Moderna, Intel, GE Aerospace, Abbott, Micron, Mobileye, Venture Global, and More - Barron's
Abbott Laboratories (NYSE:ABT) Misses Q4 CY2025 Revenue Estimates, Stock Drops - Finviz
Earnings snapshot: Abbott Laboratories Q4 beats profit estimates, but misses on revenue; initiates Q1 and FY26 outlook - MSN
Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms - marketscreener.com
Abbott slumps after reporting sales miss, disappointing Q1 guidance - Sherwood News
Abbott falls as fourth quarter revenue misses expectations By Investing.com - Investing.com South Africa
Abbott sinks after 1Q profit forecast falls short - The Edge Malaysia
Abbott stock slumps. The nutrition business is a drag on earnings. - MSN
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.74%
자본화:
|
볼륨(24시간):